Cartesian Therapeutics, Inc. (RNAC) Tuesday announced positive updated data from the Phase 2b trial of Descartes-08 in people with myasthenia gravis (MG), an autoimmune disease that causes weakness in the voluntary muscles. The company's shares were up more than 5 percent in pre-market.
As previously announced, the trial had met its primary goal.
New data from the Phase 2b study showed that Descartes-08 provided deep and durable improvements over time for MG patients, with 5.5 reduction in MG Activities of Daily Living (MG-ADL) at Month 4. Durable responses were observed through Month 12, with 80 percent of participants showed a reduction in MG-ADL score of at least 2 points.
A Phase 3 study of Descartes-08, dubbed AURORA, is planned to begin in the first half of 2025.
Cartesian Therapeutics stock had closed at $19.57, up 3.93 percent on Monday. It has traded in the range of $11.66 - $41.87 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.